Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SYHA1805 in Healthy Adults
NCT04645901Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing SYHA1805 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) or non-serious adverse events (AEs). Status: unknown.
02
Drugs
SYHA1805
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04645901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645901.